Reasonable to expect some coronavirus vaccine by year-end, Pentagon researcher says

  • World
  • Wednesday, 03 Jun 2020

FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020. REUTERS/Dado Ruvic/Illustration

WASHINGTON (Reuters) - A senior U.S. Army vaccine researcher said on Tuesday it was reasonable to expect that some sort of coronavirus vaccine could be available to part of the U.S. population by the end of the year.

Defense Secretary Mark Esper vowed on May 15 that the U.S. military and other parts of the government would, in collaboration with the private sector, produce a vaccine at scale to treat the American people and partners abroad by year-end.

Colonel Wendy Sammons-Jackson, director of the U.S. Military Infectious Disease Research Program, told a Pentagon news briefing it was "reasonable to expect that there will be some form of a vaccine that could be available at some level, to a certain population, by the end of the year."

Another Army researcher, Dr. Kayvon Modjarrad, said researchers were learning about the new virus "faster than we have about any other virus before."

"So, going to a vaccine in a matter of months, from concept all the way to Phase 3 clinical trials and potentially licensure is unprecedented. But in this case I think very much is possible."

Army researchers said work was underway with U.S. and international companies, including AstraZeneca PLC , Johnson & Johnson , Moderna Inc and Sanofi SA , to develop anti-body drugs and vaccines and the military planned to test its own vaccine candidate on humans in the late summer.

Scientists leading U.S. efforts told Reuters in late May the United States plans a massive testing effort involving more than 100,000 volunteers and a half dozen or so of the most promising vaccine candidates to deliver a safe and effective one by the end of 2020.

Other U.S. authorities, including the National Institutes of Health and the Biomedical Advanced Research and Development Authority, are also helping companies develop vaccines and therapies.

(Reporting by David Brunnstrom, Carl O'Donnell and Julie Steenhuysen; Editing by Chris Reese, Leslie Adler and Tom Brown)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3

Did you find this article insightful?


100% readers found this article insightful

Next In World

Turkey's pro-Kurdish party faces rising pressure after raid
Stop hoarding COVID-19 vaccines, South Africa's Ramaphosa tells rich nations
Watchdog probes if DOJ officials tried to overturn election
Aid workers warn on COVID-19 in camps for Mozambique cyclone victims
Keep your supply promises, EU tells vaccine makers as deliveries wobble
Who's a good doggy? Martha Stewart launches cannabis pet products
Factbox-Italy PM Conte resigns, scenarios for what comes next
Italian Prime Minister Conte resigns, president to start consultations - statement
Russia says "vigorous efforts" needed to extend New START arms treaty
Blast heard in Saudi capital Riyadh - Reuters correspondent

Stories You'll Enjoy